Evaluation of the safety of children’s vaccination with combined preparations containing whole-cell or acellular pertussis vaccine


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper comparatively analyzes the frequency and clinical manifestations of adverse events after injection of combined vaccines containing whole-cell (DTwP) or acellular (Infanrix, Pentaxim) pertussis components. The incidence of the adverse events after administration of the combined vaccines with a whole cell or acellular pertussis component is not found to differ (DTwP (0.8%), Infanrix (0.6%), Pentaxim (0.4%)). Short-term moderate health problems developed after injection of the vaccines in most (80 -98%) cases. Administration of the whole-cell vaccine significantly more frequently caused serious undesirable events from vaccination as a local abscess (21 cases), suggesting the higher safety profile of preparations containing an acellular pertussis component. By considering the complex vaccination schedule for children of the first year of life in the national immunization calendar of the Russian Federation, Pentaxim is the vaccine of choice in reducing an injection load.

Full Text

Restricted Access

About the authors

Olga A. Petina

City Consulting and Diagnostic Centre for Specific Immunoprophylaxis, Moscow Healthcare Department

Email: salkina-olga@mail.ru
Moscow

L. N Bolshakova

City Consulting and Diagnostic Centre for Specific Immunoprophylaxis, Moscow Healthcare Department

Email: bln55@yandex.ru
Moscow

I. A Leshkevich

City Consulting and Diagnostic Centre for Specific Immunoprophylaxis, Moscow Healthcare Department

Email: info@gkdcsimosgorzdrav.ru
Moscow

M. P Kostinov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vaccinums@gmail.com
Moscow

References

  1. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2013 году». http://www.rospotrebnadzor.ru
  2. Корженкова М.П., Малышев Н.А., Максимова Н.М. Маркина С.С., Черкасова В.В., Шестакова О.М., Базарова М.В. Уроки дифтерии. БИОпрепараты 2011; 2(42): 30-35.
  3. Fine P.E., Clarkson J.A. The recurrence of whooping cough; possible implications for assessment of vaccine efficacy. Lancet 1982; 1: 666-668.
  4. Kimura M., Kuno-Sakai H. Developments in pertussis immunization in Japan. Lancet 1990; 336: 30-32.
  5. Сведения об инфекционных и паразитарных заболеваниях (форма 1) за январь-декабрь 2013 года (Российская Федерация). http://www.rospotrebnadzor.ru
  6. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2012 году». http://www.rospotrebnadzor.ru
  7. ВОЗ. Совещание Стратегической консультативной группы экспертов по иммунизации, апрель 2014 -выводы и рекомендации. Еженедельный эпидемиологический бюллетень 2014; 89(21): 221-236.
  8. Boyce T.G., Virk A. While Waiting for Better Pertussis Vaccines, Let’s Use the Ones We Have. J Infect Dis. 2015; 211(7): 1196-1197.
  9. Hawken S., Manuel D.G., Deeks S.L., Kwong J.C., Crowcroft N.S., Wilson K. Underestimating the safety benefits of a new vaccine. The impact of whole-cell versus acellular pertussis vaccine on health services utilization. Am. J. Epidemiol. 2012; 176(11): 1035-1042.
  10. Beyazova U., Yüksel N., Aksakal F.N., Camurdan A.D. Comparison of the reactogenicity of three different immunization schedules including diphtheria, tetanus, pertussis, Haemophilus influenza b and polio vaccine in Turkey. Trans. R. Soc. Trop. Med. Hyg. 2013; 107(7): 438443.
  11. Plotkin S.A., Liese J., Madhi S.A., Ortiz E. Вакцина АбКДС-ИПВ//PRP~ T: обзор 16-летнего опыта клинического применения. Вопросы современной педиатрии 2012; 1(11): 19-36.
  12. Харит С.М., Черняева Т.В., Лакоткина Е.А., Иозефович О.В. Нежелательные явления после вакцинации (диагностика, лечение и профилактика). Пособие для практического врача. СПб: НИИДИ, 2013. 110 c.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies